HLS Therapeutics Inc.
TSX:HLS.TODrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $116.32M
- Beta
- 0.85
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.33
Volume 0.04M
Average 0.01M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
HLS Therapeutics Inc.
TSX:HLS.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -2.8% | +11.5% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -2.8% over three years. Forward estimates point to Revenue at +11.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Amneal Pharmaceuticals, Inc. NASDAQ:AMRX | $7.45B | $21.38 | Fairly Valued | 43.4 | +89.93% |
Bausch Health Companies Inc. NYSE:BHC | $3.13B | $8.35 | Undervalued | -1.5 | +44.30% |
Eton Pharmaceuticals, Inc. NASDAQ:ETON | $1.84B | $63.93 | Undervalued | -597.6 | +268.55% |
Aquestive Therapeutics, Inc. NASDAQ:AQST | $491.44M | $3.91 | Not rated | -8.3 | -35.16% |
Minerva Neurosciences, Inc. NASDAQ:NERV | $114.62M | $2.30 | Not rated | -0.2 | -49.30% |
Cumberland Pharmaceuticals Inc. NASDAQ:CPIX | $88.10M | $5.88 | Overvalued | -11.5 | +242.19% |
Continue the stock analysis
Jump to another research area for this company.